REG - Adv Medical Solutns. - Director/PDMR and PCA Shareholding

Advanced Medical SolutionsAnnouncement

25/09/2025 18:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250925:nRSY8901Aa&default-theme=true

RNS Number : 8901A  Advanced Medical Solutions Grp PLC  25 September 2025

     25 September 2025

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that it was
notified on 24 September 2025 that on the same day Chris Meredith, who is a
Director and PDMR, transferred, through sale and repurchase, a total of 50,510
Ordinary Shares of 5p held on his behalf held in the name of Platform
Securities Nominees Limited ("Nominee"), at a sale price of 218.5p per
Ordinary Share to (i) a combination of Individual Savings Accounts ("ISA's")
and Self-Invested Personal Pensions (SIPP's) held in the name of Chris
Meredith and Ingrid Meredith; and (ii) his adult Children, all at a price of
218.54p per Ordinary Share.

 

The number of shares, and the beneficial ownership of the shares, held by
Chris Meredith, Ingrid Meredith and his PCA's remains unchanged. These
transactions are part of normalised tax planning.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name:

     (i)   Chris Meredith

     (ii)   Ingrid Meredith
 2.  Reason for the notification
 a)  Position/status:

(i)    Chief Executive Officer
     (ii)    Wife of Chris Meredith
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        (i) Sale of 50,510 Ordinary Shares of 5p held in the name of
     the Nominee

     ·        (ii) Purchase of 9,934 Ordinary Shares of 5p into ISA's held
     in the name of Chris Meredith

     ·        (iii) Purchase of 9,932 Ordinary Shares of 5p into ISA's held
     in the name of Ingrid Meredith

     ·        (iv) Purchase of 2,257 Ordinary Shares of 5p into SIPP's held
     in the name of Chris Meredith

     ·        (v) Purchase of 1,300 Ordinary Shares of 5p into SIPP's held
     in the name of Ingrid Meredith
 c)  Price(s) and volume(s):

Price(s)       Volume(s)
     (i)  218.5p    50,510
     (ii) 218.54p   9,934
     (iii) 218.54p  9,932
     (iv) 218.54p   2,257
     (v) 218.54p    1,300
 d)  Aggregated information:

     Aggregated volume:

     (i) 50,510

     (ii - v) 23,423

     Aggregated price:

     (i) 218.5p

     (ii - v) 218.54p
 e)  Date of the transaction: 24/09/2025
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

d)

Aggregated information:

Aggregated volume:

(i) 50,510

(ii - v) 23,423

 

Aggregated price:

(i) 218.5p

(ii - v) 218.54p

e)

Date of the transaction: 24/09/2025

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Optimum Strategic Communications                 Tel: +44 (0) 20 4566 8543
 Mary Clark / Nick Bastin / Isabelle Abdou        AMS@optimumcomms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                         Tel: +44 (0)20 3207 7800
 Toby Flaux / Detlir Elezi / Yasmina Benchekroun

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®), LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G(®). AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(®) brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,600 employee For more information, please see
www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFEEAVIEFIE